Cipla's Quarterly Profit Falls 35% as North American Drug Sales Weaken

Indian pharmaceutical company Cipla reported a 35% year-on-year decline in consolidated net profit for the quarter ended September 30, 2026, as weaker North American sales outweighed growth in its domestic business.

The company reported profit after tax of approximately ₹878 crore, down from about ₹1,351 crore a year earlier. Revenue from operations decreased 2.4% to ₹7,404 crore from ₹7,589 crore. The results were released on October 27 and relate to the second quarter of Cipla's financial year 2026-27.

North American revenue fell 19% year on year to $172 million, compared with $233 million in the corresponding quarter of the previous financial year. The company said the business nevertheless improved sequentially from $162 million in the preceding quarter. These figures show that sales can recover from one quarter to the next while remaining below the previous year's level.

India provided a contrast. Cipla's domestic business recorded 12% year-on-year revenue growth, supported by its branded prescription portfolio. The different trajectories in the two markets help explain why stronger performance at home did not prevent an overall decline in quarterly profit.

The company's earnings before interest, taxes, depreciation and amortisation fell about 27% from a year earlier to ₹1,388 crore. Its reported operating margin was approximately 18.7%, below the level recorded a year earlier. Profitability therefore weakened more sharply than revenue.

Cipla said it invested ₹423 crore in research and development during the quarter, equivalent to approximately 5.7% of sales. The spending was directed toward product filings and development programmes, which may support future launches but do not guarantee their commercial success.

Management said it remains focused on rebuilding the North American business through its product pipeline and continued commercialisation. That expectation is a company outlook rather than a confirmed future result. Regulatory decisions, competition from other generic drugmakers and the timing of product introductions will affect the outcome.

The latest figures highlight the challenge of balancing a growing Indian market with slower sales in North America, one of the company's other major revenue sources. Future earnings reports will show whether the sequential improvement in North America develops into sustained annual growth.